AMVUTTRA is a drug for the treatment of nerve damage in adult patients with hereditary transthyretin-mediated amyloidosis. Transthyretin-mediated amyloidosis is the buildup of abnormal deposits of a substance called amyloid in the body's organs and tissues. Amyloid disrupts the function of organs and tissues.
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshots-amvuttra
No hay comentarios:
Publicar un comentario